Does the media prefer ARDX or DNTH?

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 4 mentions for Ardelyx. Dianthus Therapeutics' average media sentiment score of 1.08 beat Ardelyx's score of 1.02 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARDX or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Oruka Therapeutics and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.02 beat Oruka Therapeutics' score of 0.85 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARDX or MANE more profitable?

Veradermics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Veradermics' return on equity of 0.00% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% Veradermics N/A N/A N/A

Does the media prefer ARDX or MANE?

In the previous week, Ardelyx had 1 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Veradermics. Ardelyx's average media sentiment score of 1.02 beat Veradermics' score of 0.02 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ARDX or KNSA?

In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.02 beat Kiniksa Pharmaceuticals International's score of 0.70 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals International 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GRFS or ARDX?

Grifols has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.58 $454.82M $0.19 37.89 Ardelyx $407.32M 3.12 -$61.60M -$0.23 N/A

Is GRFS or ARDX more profitable?

Grifols has a net margin of 5.54% compared to Ardelyx's net margin of -13.58%. Grifols' return on equity of 6.21% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Ardelyx -13.58% -38.11% -11.85%

Does the media favor GRFS or ARDX?

In the previous week, Grifols and Grifols both had 4 articles in the media. Grifols' average media sentiment score of 1.39 beat Ardelyx's score of 1.02 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ardelyx (ARDX) Competitors

$5.14 -0.14 (-2.65%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$5.14 0.00 (-0.10%)

As of 07/13/2026 07:46 PM Eastern

Compare

ARDX vs. DNTH, ORKA, MANE, KNSA, and GRFS

Should you buy Ardelyx stock or one of its competitors? MarketBeat compares Ardelyx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ardelyx include Dianthus Therapeutics (DNTH), Oruka Therapeutics (ORKA), Veradermics (MANE), Kiniksa Pharmaceuticals International (KNSA), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Ardelyx compare to Dianthus Therapeutics?

Ardelyx (NASDAQ:ARDX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Ardelyx has a net margin of -13.58% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Dianthus Therapeutics and 4 mentions for Ardelyx. Dianthus Therapeutics' average media sentiment score of 1.08 beat Ardelyx's score of 1.02 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx presently has a consensus price target of $15.73, indicating a potential upside of 205.98%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 19.44%. Given Ardelyx's higher probable upside, research analysts clearly believe Ardelyx is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Ardelyx has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Ardelyx has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.12	-$61.60M	-$0.23	N/A
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ardelyx beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Oruka Therapeutics?

Ardelyx (NASDAQ:ARDX) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Ardelyx has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Ardelyx. MarketBeat recorded 7 mentions for Oruka Therapeutics and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.02 beat Oruka Therapeutics' score of 0.85 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx presently has a consensus price target of $15.73, indicating a potential upside of 205.98%. Oruka Therapeutics has a consensus price target of $134.30, indicating a potential upside of 58.82%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oruka Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Oruka Therapeutics' return on equity of -26.16% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Ardelyx has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.12	-$61.60M	-$0.23	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Ardelyx beats Oruka Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Veradermics?

Ardelyx (NASDAQ:ARDX) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Veradermics has lower revenue, but higher earnings than Ardelyx. Veradermics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.12	-$61.60M	-$0.23	N/A
Veradermics	N/A	N/A	N/A	-$1.32	N/A

In the previous week, Ardelyx had 1 more articles in the media than Veradermics. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Veradermics. Ardelyx's average media sentiment score of 1.02 beat Veradermics' score of 0.02 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ardelyx presently has a consensus price target of $15.73, suggesting a potential upside of 205.98%. Veradermics has a consensus price target of $135.60, suggesting a potential upside of 22.83%. Given Ardelyx's stronger consensus rating and higher possible upside, equities analysts clearly believe Ardelyx is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Veradermics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Veradermics' return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Veradermics	N/A	N/A	N/A

Summary

Ardelyx beats Veradermics on 11 of the 14 factors compared between the two stocks.

How does Ardelyx compare to Kiniksa Pharmaceuticals International?

Ardelyx (NASDAQ:ARDX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.12	-$61.60M	-$0.23	N/A
Kiniksa Pharmaceuticals International	$677.56M	6.92	$59.01M	$0.90	67.71

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Ardelyx's net margin of -13.58%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Ardelyx currently has a consensus target price of $15.73, indicating a potential upside of 205.98%. Kiniksa Pharmaceuticals International has a consensus target price of $65.14, indicating a potential upside of 6.90%. Given Ardelyx's higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Ardelyx. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 4 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.02 beat Kiniksa Pharmaceuticals International's score of 0.70 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats Ardelyx on 11 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Grifols?

Grifols (NASDAQ:GRFS) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Grifols has a net margin of 5.54% compared to Ardelyx's net margin of -13.58%. Grifols' return on equity of 6.21% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Ardelyx	-13.58%	-38.11%	-11.85%

In the previous week, Grifols and Grifols both had 4 articles in the media. Grifols' average media sentiment score of 1.39 beat Ardelyx's score of 1.02 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89
Ardelyx	$407.32M	3.12	-$61.60M	-$0.23	N/A

Grifols presently has a consensus target price of $10.00, indicating a potential upside of 38.89%. Ardelyx has a consensus target price of $15.73, indicating a potential upside of 205.98%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Grifols has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

58.9% of Ardelyx shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Grifols beats Ardelyx on 9 of the 16 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-22.35	19.17	27.11	24.26
Price / Sales	3.12	838.79	587.92	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	7.45	4.22	10.75	6.29
Net Income	-$61.60M	$64.26M	$3.58B	$330.66M
7 Day Performance	-4.46%	-3.58%	-2.06%	-1.32%
1 Month Performance	-9.67%	2.12%	3.32%	-0.64%
1 Year Performance	11.50%	20.35%	26.35%	19.08%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	3.3877 of 5 stars	$5.14 -2.7%	$15.73 +206.0%	+14.5%	$1.30B	$407.32M	N/A	90
DNTH Dianthus Therapeutics	2.8348 of 5 stars	$93.34 -1.1%	$117.82 +26.2%	+391.7%	$5.16B	$2.04M	N/A	80	News Coverage Insider Trade
ORKA Oruka Therapeutics	3.2001 of 5 stars	$83.13 -2.4%	$134.30 +61.6%	+494.2%	$5.14B	N/A	N/A	N/A	News Coverage Analyst Forecast Insider Trade Gap Down
MANE Veradermics	2.8089 of 5 stars	$122.08 -5.9%	$114.20 -6.5%	N/A	$5.10B	N/A	N/A	19	Analyst Downgrade
KNSA Kiniksa Pharmaceuticals International	3.1798 of 5 stars	$62.77 -2.7%	$62.71 -0.1%	+116.9%	$4.96B	$677.56M	69.74	220	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. DNTH, ORKA, MANE, KNSA, and GRFS

How does Ardelyx compare to Dianthus Therapeutics?

Summary

How does Ardelyx compare to Oruka Therapeutics?

Summary

How does Ardelyx compare to Veradermics?

Summary

How does Ardelyx compare to Kiniksa Pharmaceuticals International?

Summary

How does Ardelyx compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. DNTH, ORKA, MANE, KNSA, and GRFS

How does Ardelyx compare to Dianthus Therapeutics?

Is ARDX or DNTH more profitable?

Does the media prefer ARDX or DNTH?

Do analysts prefer ARDX or DNTH?

Which has more risk & volatility, ARDX or DNTH?

Which has preferable valuation and earnings, ARDX or DNTH?

Do institutionals & insiders believe in ARDX or DNTH?

Summary

How does Ardelyx compare to Oruka Therapeutics?

Which has more risk & volatility, ARDX or ORKA?

Does the media prefer ARDX or ORKA?

Do analysts rate ARDX or ORKA?

Do insiders and institutionals have more ownership in ARDX or ORKA?

Is ARDX or ORKA more profitable?

Which has stronger earnings & valuation, ARDX or ORKA?

Summary

How does Ardelyx compare to Veradermics?

Which has higher earnings & valuation, ARDX or MANE?

Does the media prefer ARDX or MANE?

Do analysts recommend ARDX or MANE?

Do insiders & institutionals believe in ARDX or MANE?

Is ARDX or MANE more profitable?

Summary

How does Ardelyx compare to Kiniksa Pharmaceuticals International?

Which has preferable earnings & valuation, ARDX or KNSA?

Is ARDX or KNSA more profitable?

Do analysts recommend ARDX or KNSA?

Do institutionals & insiders have more ownership in ARDX or KNSA?

Does the media prefer ARDX or KNSA?

Which has more risk & volatility, ARDX or KNSA?

Summary

How does Ardelyx compare to Grifols?

Is GRFS or ARDX more profitable?

Does the media favor GRFS or ARDX?

Which has preferable earnings and valuation, GRFS or ARDX?

Do analysts recommend GRFS or ARDX?

Which has more volatility & risk, GRFS or ARDX?

Do insiders & institutionals believe in GRFS or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools